drugset / Trial / NCT02065401

Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)

NCT02065401

Phase 1 Withdrawn Shire
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to compare the pharmacokinetic profiles of deferitazole after administration of granule and tablet formulations of a deferitazole disodium salt to a capsule formulation of deferitazole magnesium hydroxide salt (reference formulation) in healthy adult subjects.

Timeline

Start
2014-02-28
Primary completion
2014-03-19
Completion
2014-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject SPD602 Unknown 1500 mg Oral
Subject SPD602 Unknown 2400 mg Oral

Indications

No indication recorded.